AI Tokens
Stock Analysis on Net

Stryker Corp. (NYSE:SYK)

This company has been moved to the archive! The financial data has not been updated since April 29, 2022.

Common Stock Valuation Ratios (Price Multiples)

Microsoft Excel

Current Valuation Ratios

Stryker Corp., current price multiples

Microsoft Excel
Stryker Corp. Abbott Laboratories Elevance Health Inc. Intuitive Surgical Inc. Medtronic PLC UnitedHealth Group Inc. Health Care Equipment & Services Health Care
Selected Financial Data
Current share price (P) $241.26
No. shares of common stock outstanding 378,154,080
Growth rate (g) 6.99%
 
Earnings per share (EPS) $5.27
Next year expected EPS $5.64
Operating profit per share $6.83
Sales per share $45.24
Book value per share (BVPS) $39.34
Valuation Ratios (Price Multiples)
Price to earnings (P/E) 45.75 27.50 16.79 54.90 25.42 31.13 25.96 32.70
Price to next year expected earnings 42.77 25.50 15.01 48.13 25.08 27.73 23.36 28.54
Price-earnings-growth (PEG) 6.55 3.51 1.42 3.91 18.55 2.54 2.33 2.25
Price to operating profit (P/OP) 35.31 22.28 14.47 53.23 18.87 19.79 20.30 27.61
Price to sales (P/S) 5.33 4.05 0.48 15.58 3.36 0.85 1.85 4.98
Price to book value (P/BV) 6.13 3.44 2.17 8.80 2.47 3.99 4.49 8.31

Based on: 10-K (reporting date: 2021-12-31).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

Stryker Corp., historical price multiples

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Price to earnings (P/E) 47.65 57.72 39.24 18.96 54.36
Price to operating profit (P/OP) 36.77 41.52 30.13 26.55 24.21
Price to sales (P/S) 5.55 6.43 5.49 4.95 4.46
Price to book value (P/BV) 6.39 7.05 6.38 5.74 5.56

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


An analysis of the valuation multiples from 2017 through 2021 reveals a general trend of expansion in market premiums, peaking in 2020 before undergoing a moderate correction in 2021. While the asset-based and revenue-based ratios demonstrated a relatively steady ascent, the earnings-based multiple exhibited significant volatility over the five-year period.

Price to Earnings (P/E)
The P/E ratio experienced substantial fluctuations, starting at 54.36 in 2017 and dropping sharply to 18.96 in 2018. A strong recovery followed, with the ratio climbing to a peak of 57.72 in 2020 before moderating to 47.65 by the end of 2021. This volatility suggests significant shifts in market sentiment or earnings stability during this timeframe.
Price to Operating Profit (P/OP)
A consistent upward trajectory was observed in the P/OP ratio from 2017 to 2020, rising from 24.21 to 41.52. This indicates an increasing premium placed on the core operating performance of the entity. Similar to other metrics, a slight contraction occurred in 2021, bringing the ratio to 36.77.
Price to Sales (P/S)
The P/S ratio grew steadily from 4.46 in 2017 to 6.43 in 2020. This progression reflects a period of increasing valuation relative to top-line revenue. A correction was noted in 2021, where the ratio decreased to 5.55.
Price to Book Value (P/BV)
The P/BV ratio followed a pattern closely aligned with the P/S ratio, increasing from 5.56 in 2017 to a maximum of 7.05 in 2020. The ratio subsequently declined to 6.39 in 2021, suggesting a reduction in the market premium over the accounting value of the company's assets.

Across all four metrics, 2020 represents the peak valuation year, while 2021 marks a period of valuation normalization. The consistency across P/OP, P/S, and P/BV suggests a broad increase in market valuation that was not as linearly reflected in the P/E ratio due to its higher sensitivity to net income fluctuations.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Price to Earnings (P/E)

Stryker Corp., historical P/E calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
No. shares of common stock outstanding1 377,544,686 376,200,942 374,575,145 372,664,636 374,642,060
Selected Financial Data (US$)
Net earnings (in millions) 1,994 1,599 2,083 3,553 1,020
Earnings per share (EPS)2 5.28 4.25 5.56 9.53 2.72
Share price1, 3 251.65 245.34 218.24 180.75 148.01
Valuation Ratio
P/E ratio4 47.65 57.72 39.24 18.96 54.36
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 29.13 — — — —
Elevance Health Inc. 18.13 — — — —
Intuitive Surgical Inc. 59.94 — — — —
Medtronic PLC 46.56 — — — —
UnitedHealth Group Inc. 26.03 — — — —
P/E Ratio, Sector
Health Care Equipment & Services 28.98 — — — —
P/E Ratio, Industry
Health Care 21.55 — — — —

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
EPS = Net earnings ÷ No. shares of common stock outstanding
= 1,994,000,000 ÷ 377,544,686 = 5.28

3 Closing price as at the filing date of Stryker Corp. Annual Report.

4 2021 Calculation
P/E ratio = Share price ÷ EPS
= 251.65 ÷ 5.28 = 47.65

5 Click competitor name to see calculations.


A consistent upward trajectory in share price is observed from 2017 through 2021, with the value increasing from 148.01 US$ to 251.65 US$. This steady growth in market price contrasts with significant volatility in earnings per share and the resulting price-to-earnings multiples during the same period.

Share Price Appreciation
The share price experienced uninterrupted annual growth, rising by approximately 70% over the five-year period. The most substantial year-over-year increases occurred between 2018 and 2020.
Earnings Per Share (EPS) Volatility
EPS exhibited an erratic pattern, peaking sharply in 2018 at 9.53 US$ before declining for two consecutive years to a low of 4.25 US$ in 2020. A moderate recovery was noted in 2021, with EPS rising to 5.28 US$.
Price-to-Earnings (P/E) Ratio Dynamics
The P/E ratio fluctuated significantly, reflecting the inverse relationship between the steady share price increase and the volatile earnings. The ratio reached its lowest point in 2018 (18.96) coinciding with the peak in EPS, and reached its highest point in 2020 (57.72) when EPS hit its lowest level. By 2021, the ratio moderated to 47.65 as earnings began to recover.

The valuation profile indicates that the market maintained a high premium on the stock despite fluctuations in actual earnings. The expansion of the P/E ratio in 2020 suggests that investors were willing to pay a higher multiple for each dollar of earnings during a period of decreased profitability, highlighting strong market confidence or expectations of future growth.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Price to Operating Profit (P/OP)

Stryker Corp., historical P/OP calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
No. shares of common stock outstanding1 377,544,686 376,200,942 374,575,145 372,664,636 374,642,060
Selected Financial Data (US$)
Operating income (in millions) 2,584 2,223 2,713 2,537 2,290
Operating profit per share2 6.84 5.91 7.24 6.81 6.11
Share price1, 3 251.65 245.34 218.24 180.75 148.01
Valuation Ratio
P/OP ratio4 36.77 41.52 30.13 26.55 24.21
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 24.45 — — — —
Elevance Health Inc. 15.70 — — — —
Intuitive Surgical Inc. 56.11 — — — —
Medtronic PLC 37.44 — — — —
UnitedHealth Group Inc. 18.77 — — — —
P/OP Ratio, Sector
Health Care Equipment & Services 22.66 — — — —
P/OP Ratio, Industry
Health Care 18.20 — — — —

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
Operating profit per share = Operating income ÷ No. shares of common stock outstanding
= 2,584,000,000 ÷ 377,544,686 = 6.84

3 Closing price as at the filing date of Stryker Corp. Annual Report.

4 2021 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 251.65 ÷ 6.84 = 36.77

5 Click competitor name to see calculations.


Between 2017 and 2021, there was a consistent upward trajectory in share price and a general expansion of the Price to Operating Profit (P/OP) ratio. While market valuation grew steadily throughout the period, operating profit per share experienced volatility, which significantly influenced the valuation multiple.

Share Price Trend
A continuous increase in share price is observed, rising from 148.01 US$ in 2017 to 251.65 US$ by 2021. This suggests a sustained increase in investor demand and market capitalization over the five-year interval.
Operating Profit Per Share Performance
Operating profit per share grew from 6.11 US$ in 2017 to a peak of 7.24 US$ in 2019. A significant contraction occurred in 2020, with the value falling to 5.91 US$, before recovering to 6.84 US$ in 2021.
Price to Operating Profit (P/OP) Dynamics
The P/OP ratio increased from 24.21 in 2017 to 36.77 in 2021. A sharp spike to 41.52 was recorded in 2020, driven by the combination of a continuing rise in share price and a simultaneous decline in operating profit per share. The subsequent decrease to 36.77 in 2021 indicates a moderation in the multiple as operating profitability recovered while share price growth decelerated.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Price to Sales (P/S)

Stryker Corp., historical P/S calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
No. shares of common stock outstanding1 377,544,686 376,200,942 374,575,145 372,664,636 374,642,060
Selected Financial Data (US$)
Net sales (in millions) 17,108 14,351 14,884 13,601 12,444
Sales per share2 45.31 38.15 39.74 36.50 33.22
Share price1, 3 251.65 245.34 218.24 180.75 148.01
Valuation Ratio
P/S ratio4 5.55 6.43 5.49 4.95 4.46
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.78 — — — —
Elevance Health Inc. 0.81 — — — —
Intuitive Surgical Inc. 17.89 — — — —
Medtronic PLC 5.57 — — — —
UnitedHealth Group Inc. 1.58 — — — —
P/S Ratio, Sector
Health Care Equipment & Services 2.07 — — — —
P/S Ratio, Industry
Health Care 3.28 — — — —

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
Sales per share = Net sales ÷ No. shares of common stock outstanding
= 17,108,000,000 ÷ 377,544,686 = 45.31

3 Closing price as at the filing date of Stryker Corp. Annual Report.

4 2021 Calculation
P/S ratio = Share price ÷ Sales per share
= 251.65 ÷ 45.31 = 5.55

5 Click competitor name to see calculations.


Between 2017 and 2021, a consistent upward trajectory in share price was observed, accompanied by a general expansion in the revenue multiple that peaked in 2020 before contracting in 2021.

Share Price and Sales Performance
The share price demonstrated steady growth, rising from 148.01 in 2017 to 251.65 by the end of 2021. Sales per share generally trended upward from 33.22 in 2017 to 45.31 in 2021, although a brief decline occurred in 2020, when sales per share fell to 38.15.
Price-to-Sales (P/S) Ratio Expansion
The P/S ratio increased progressively from 4.46 in 2017 to 6.43 in 2020. This expansion indicates that the market valuation grew at a faster pace than the underlying revenue generated per share, suggesting increased investor premiums or higher growth expectations during this period.
Valuation Realignment in 2021
A reversal in the P/S trend occurred in 2021, with the ratio declining to 5.55. While the share price continued to rise to 251.65, the valuation multiple contracted because the growth in sales per share—which surged from 38.15 to 45.31—outpaced the increase in stock price.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Price to Book Value (P/BV)

Stryker Corp., historical P/BV calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
No. shares of common stock outstanding1 377,544,686 376,200,942 374,575,145 372,664,636 374,642,060
Selected Financial Data (US$)
Total Stryker shareholders’ equity (in millions) 14,877 13,084 12,807 11,730 9,966
Book value per share (BVPS)2 39.40 34.78 34.19 31.48 26.60
Share price1, 3 251.65 245.34 218.24 180.75 148.01
Valuation Ratio
P/BV ratio4 6.39 7.05 6.38 5.74 5.56
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 5.75 — — — —
Elevance Health Inc. 3.07 — — — —
Intuitive Surgical Inc. 8.59 — — — —
Medtronic PLC 3.26 — — — —
UnitedHealth Group Inc. 6.27 — — — —
P/BV Ratio, Sector
Health Care Equipment & Services 5.01 — — — —
P/BV Ratio, Industry
Health Care 5.48 — — — —

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
BVPS = Total Stryker shareholders’ equity ÷ No. shares of common stock outstanding
= 14,877,000,000 ÷ 377,544,686 = 39.40

3 Closing price as at the filing date of Stryker Corp. Annual Report.

4 2021 Calculation
P/BV ratio = Share price ÷ BVPS
= 251.65 ÷ 39.40 = 6.39

5 Click competitor name to see calculations.


Between 2017 and 2021, a consistent upward trajectory is observed in both the market valuation and the underlying book value per share, although the rate of growth diverged across the period.

Share Price Appreciation
The share price exhibited steady growth over the five-year period, rising from 148.01 US$ in 2017 to 251.65 US$ by the end of 2021. The most pronounced increases occurred between 2017 and 2019, followed by a deceleration in the growth rate through 2021.
Book Value Per Share (BVPS) Growth
A positive trend is noted in the book value per share, which increased from 26.60 US$ in 2017 to 39.40 US$ in 2021. This indicates a consistent increase in the company's net asset value relative to its outstanding shares.
Price to Book Value (P/BV) Dynamics
The P/BV ratio trended upward for the first four years, moving from 5.56 in 2017 to a peak of 7.05 in 2020. This expansion suggests that the market price grew at a faster rate than the accounting book value during this window. In 2021, a correction occurred, with the ratio declining to 6.39. This contraction was driven by a significant increase in BVPS, which outpaced the marginal increase in share price for that year.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?